Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors | ||
By: GlobeNewswire - 29 May 2020 | Back to overview list |
|
Addition of Tomivosertib Conferred Benefit in Subjects Progressing on Checkpoint Inhibitors Alone Data presented at the American Society for Clinical Oncology 2020 Virtual Scientific Program SAN DIEGO, May 29, 2020 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today announced that positive Phase 2 data from its pipeline program tomivosertib (eFT508), will be presented at the ASCO 2020 Virtual Scientific Program at 8:00 a.m. ET on May 29. The data demonstrates tomivosertib’s potential as a therapeutic solution for common resistance mechanisms to checkpoint inhibitors. In a Phase 2 study, open-label study, tomivosertib demonstrated antitumor activity in combination with check point inhibitors (CPI) in patients with solid tumors who progressed on CPI treatment. In the study, 41% of patients with non-small cell lung cancer treated with tomivosertib showed progression free survival at 24 weeks. The median progression free survival rate was 19 weeks, and all NSCLC subjects entered the study with progression by RECIST 1.1 on single agent checkpoint inhibitor prior to adding tomivosertib. “Tomivosertib was designed to down regulate multiple immunosuppressive factors by acting at the level of mRNA translation and our clinical data continue to highlight the potential of tomivosertib to complement focused immune checkpoint inhibitor activity such as anti-PD-1 and PD-L1 agents,” said Steve Worland, Ph.D., president and chief executive officer of eFFECTOR. “This study underscores the importance of progression free survival for patients who may experience extended and improved quality of life on checkpoint inhibitors with the addition of tomivosertib prior to switching to cytotoxic salvage therapy.” Secondary objectives for the current study include characterizing the pharmacokinetics and safety of tomivosertib when added to an anti-PD-1/anti PD-L1 therapy. There were no grade 5 treatment-emergent adverse events (TEAEs) related to tomivosertib and the majority of TEAEs were grade 1 or 2. About Tomivosertib (eFT508) Please visit www.clinicaltrials.gov for further information on ongoing clinical studies of tomivosertib. About eFFECTOR Contacts: Media: |
||
|
||
Copyright 2020 GlobeNewswire | Back to overview list |